Dexcom faces mounting scrutiny over G7 safety concerns, FDA violations, financial practices, and growing competition from Abbott's Libre 3.

DexCom, Inc. (NASDAQ:DXCM) is one of the best growth stocks to buy and hold forever. On September 22, UBS reiterated a ‘Buy’ rating on the stock and a $106 price target. The research firm reiterated ...

DexCom (DXCM) stock declines after a short report, yet analysts from TD Cowen and Baird stay bullish on the company's prospects. Read more here.

DexCom, Inc. is a medical device company, which engages in the design, development, and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include ...

As the effects of climate change and ecological decline intensify, the need for accurate, scalable environmental monitoring has never been more urgent. From tracking urban air quality to safeguarding ...

Shares of DexCom (DXCM) declined 10% on Friday after investment firm Hunterbrook Capital disclosed a short position in the stock. Hunterbrook said on Thursday that it has a short position on DXCM ...

Shares of medical device company DexCom (NASDAQ:DXCM) fell 7.4% in the morning session after a short-seller report from Hunterbrook Capital alleged issues with the company's G7 glucose monitoring ...

Chris has reported for various tech and consumer goods outlets over the past decade, including Android Police since early 2022. Previously, he has contributed to outlets such as NotebookCheck, and ...

Telemedicine refers to the provision of remote clinical services, via real-time two-way communication between the patient and the healthcare provider, using electronic audio and visual means. In ...